Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D Solomon

Showing results (1421-1430 of 1,873) with videos related to

Pageof 188
Sort By:
JACC. Heart Failure|December 14, 2020
Treatment of HF in an Era of Multiple Therapies: Statement From the HF CollaboratoryAnkeet S Bhatt, William T Abraham, JoAnn Lindenfeld, et al.
Nature Medicine|October 6, 2025
Lifetime benefits of comprehensive medical therapy in heart failure with mildly reduced or preserved ejection fractionMuthiah Vaduganathan, Brian L Claggett, Safia Chatur, et al.
Journal of the American College of Cardiology|November 6, 2024
Artificial Intelligence in Cardiovascular Clinical TrialsJonathan W Cunningham, William T Abraham, Ankeet S Bhatt, et al.
European Journal of Heart Failure|November 20, 2024
Effects of sacubitril/valsartan according to background beta-blocker therapy in patients with heart failure and reduced ejection fraction: Insights from PARADIGM-HFSharmistha Datta Gupta, Jawad H Butt, Eoghan G M McMurray, et al.
Journal of Cardiac Failure|April 8, 2026
Performance of the HFpEF-ABA, H<sub>2</sub>FPEF, and HFA-PEFF Algorithms in HFpEF: A Participant-Level Pooled Analysis of Randomized Clinical TrialsJohn W Ostrominski, Fernando A Lara Lince, Brian L Claggett, et al.
Journal of the American College of Cardiology|August 27, 2025
Adiposity-Related Anthropometrics and Clinical Outcomes in Heart Failure With Mildly Reduced or Preserved Ejection Fraction: A Participant-Level Pooled Analysis of Randomized Clinical TrialsJohn W Ostrominski, Mats C Højbjerg Lassen, Jawad H Butt, et al.
The American Journal of Cardiology|October 27, 2019
Assessment of Predictors of Left Atrial Volume Response to a Transcatheter InterAtrial Shunt Device (from the REDUCE LAP-HF Trial)Thomas C Hanff, David M Kaye, Christopher S Hayward, et al.
Journal of the American College of Cardiology|September 2, 2025
Natriuretic Peptides, Body Mass Index, and Clinical Outcomes in Heart Failure with Mildly Reduced or Preserved Ejection FractionJohn W Ostrominski, Brendon L Neuen, Brian L Claggett, et al.
JAMA Cardiology|August 7, 2024
Rates of Sudden Death After Myocardial Infarction-Insights From the VALIANT and PARADISE-MI TrialsJames P Curtain, Marc A Pfeffer, Eugene Braunwald, et al.
Journal of the American College of Cardiology|February 2, 2018
Improving Heart Failure Therapeutics Development in the United States: The Heart Failure CollaboratoryChristopher M O'Connor, Mitchell A Psotka, Mona Fiuzat, et al.
Pageof 188

Showing results (1421-1430 of 1,873) with videos related to

Sort By:
Pageof 188
JACC. Heart Failure|December 14, 2020
Treatment of HF in an Era of Multiple Therapies: Statement From the HF CollaboratoryAnkeet S Bhatt, William T Abraham, JoAnn Lindenfeld, et al.
Nature Medicine|October 6, 2025
Lifetime benefits of comprehensive medical therapy in heart failure with mildly reduced or preserved ejection fractionMuthiah Vaduganathan, Brian L Claggett, Safia Chatur, et al.
Journal of the American College of Cardiology|November 6, 2024
Artificial Intelligence in Cardiovascular Clinical TrialsJonathan W Cunningham, William T Abraham, Ankeet S Bhatt, et al.
European Journal of Heart Failure|November 20, 2024
Effects of sacubitril/valsartan according to background beta-blocker therapy in patients with heart failure and reduced ejection fraction: Insights from PARADIGM-HFSharmistha Datta Gupta, Jawad H Butt, Eoghan G M McMurray, et al.
Journal of Cardiac Failure|April 8, 2026
Performance of the HFpEF-ABA, H<sub>2</sub>FPEF, and HFA-PEFF Algorithms in HFpEF: A Participant-Level Pooled Analysis of Randomized Clinical TrialsJohn W Ostrominski, Fernando A Lara Lince, Brian L Claggett, et al.
Journal of the American College of Cardiology|August 27, 2025
Adiposity-Related Anthropometrics and Clinical Outcomes in Heart Failure With Mildly Reduced or Preserved Ejection Fraction: A Participant-Level Pooled Analysis of Randomized Clinical TrialsJohn W Ostrominski, Mats C Højbjerg Lassen, Jawad H Butt, et al.
The American Journal of Cardiology|October 27, 2019
Assessment of Predictors of Left Atrial Volume Response to a Transcatheter InterAtrial Shunt Device (from the REDUCE LAP-HF Trial)Thomas C Hanff, David M Kaye, Christopher S Hayward, et al.
Journal of the American College of Cardiology|September 2, 2025
Natriuretic Peptides, Body Mass Index, and Clinical Outcomes in Heart Failure with Mildly Reduced or Preserved Ejection FractionJohn W Ostrominski, Brendon L Neuen, Brian L Claggett, et al.
JAMA Cardiology|August 7, 2024
Rates of Sudden Death After Myocardial Infarction-Insights From the VALIANT and PARADISE-MI TrialsJames P Curtain, Marc A Pfeffer, Eugene Braunwald, et al.
Journal of the American College of Cardiology|February 2, 2018
Improving Heart Failure Therapeutics Development in the United States: The Heart Failure CollaboratoryChristopher M O'Connor, Mitchell A Psotka, Mona Fiuzat, et al.
Pageof 188